<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430429</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0801-03</org_study_id>
    <nct_id>NCT01430429</nct_id>
  </id_info>
  <brief_title>Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody</brief_title>
  <acronym>PIANO</acronym>
  <official_title>An Open Label Single Arm Study to Investigate the Safety and Efficacy of Multiple Administrations of NI-0801, a Fully Human Anti-CXCL10 Monoclonal Antibody in PBC Patients With an Incomplete Response to Ursodeoxycholic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess safety and efficacy of multiple doses of NI-0801 in
      primary biliary cirrhosis patients with an inadequate response to ursodeoxycholic acid.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>1</number_of_arms>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>NI-0801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NI-0801</intervention_name>
    <arm_group_label>NI-0801</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proven primary biliary cirrhosis (PBC), as demonstrated by the presence of at least 2
             of the following 3 diagnostic factor (History of increased alkaline phosphatase levels
             for at least 6 months; positive serum AMA titer; Liver biopsy consistent with PBC)

          -  Elevated liver enzyme levels at screening

          -  Have given written informed consent

        Exclusion Criteria:

          -  Screening bilirubin &gt; 2.9 mg/dL (50 Î¼mol/L)

          -  Screening creatinine clearance &lt; 80 ml/min

          -  History or presence of hepatic decompensation (e.g., esophageal variceal bleeding,
             hepatic encephalopathy, or ascites)

          -  Positive serology result for Human Immunodeficiency Virus (HIV), Hepatitis B or C

          -  Known or previous diagnosis of malignancy

          -  Presence of any active infection

          -  Previous history of active TB within 12 months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIHR Liver Biomedical Research Unit, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2011</study_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

